Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:IBRX NASDAQ:RVMD NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$59.71+0.2%$46.48$29.31▼$61.48$7.08B0.671.91 million shs20,422 shsIBRXImmunityBio$2.42-2.6%$2.49$1.83▼$7.48$2.37B0.278.22 million shs462,127 shsRVMDRevolution Medicines$48.19-1.2%$41.28$29.17▼$62.40$8.97B1.271.90 million shs16,822 shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.12$31.09▼$106.93$9.21B0.051.46 million shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-0.75%-1.73%+16.55%+56.77%+8.58%IBRXImmunityBio+5.08%-1.98%-4.62%-9.49%-32.05%RVMDRevolution Medicines+1.06%+4.66%+4.73%+28.93%-3.43%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%+0.45%+2.04%+227.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$59.71+0.2%$46.48$29.31▼$61.48$7.08B0.671.91 million shs20,422 shsIBRXImmunityBio$2.42-2.6%$2.49$1.83▼$7.48$2.37B0.278.22 million shs462,127 shsRVMDRevolution Medicines$48.19-1.2%$41.28$29.17▼$62.40$8.97B1.271.90 million shs16,822 shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.12$31.09▼$106.93$9.21B0.051.46 million shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-0.75%-1.73%+16.55%+56.77%+8.58%IBRXImmunityBio+5.08%-1.98%-4.62%-9.49%-32.05%RVMDRevolution Medicines+1.06%+4.66%+4.73%+28.93%-3.43%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%+0.45%+2.04%+227.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.76Moderate Buy$76.6428.36% UpsideIBRXImmunityBio 2.83Moderate Buy$10.75345.13% UpsideRVMDRevolution Medicines 2.93Moderate Buy$74.6454.91% UpsideVRNAVerona Pharma PLC American Depositary Share 2.07Hold$109.001.95% UpsideCurrent Analyst Ratings BreakdownLatest IBRX, VRNA, RVMD, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CYTKCytokineticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025RVMDRevolution MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VRNAVerona Pharma PLC American Depositary ShareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VRNAVerona Pharma PLC American Depositary ShareCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$100.0010/6/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$71.00 ➝ $82.0010/2/2025CYTKCytokineticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$52.00 ➝ $56.009/29/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.009/27/2025CYTKCytokineticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IBRXImmunityBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RVMDRevolution MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VRNAVerona Pharma PLC American Depositary ShareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M386.84N/AN/A($1.15) per share-51.92IBRXImmunityBio$14.74M161.38N/AN/A($0.57) per share-4.24RVMDRevolution Medicines$11.58M777.83N/AN/A$13.47 per share3.58VRNAVerona Pharma PLC American Depositary Share$42.28M217.94N/AN/A$2.56 per share41.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,563.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest IBRX, VRNA, RVMD, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025IBRXImmunityBio-$0.10N/AN/AN/A$31.88 millionN/A11/5/2025Q3 2025CYTKCytokinetics-$1.59N/AN/AN/A$6.05 millionN/A11/5/2025Q3 2025RVMDRevolution Medicines-$1.39N/AN/AN/A$1.81 millionN/A11/3/2025Q3 2025VRNAVerona Pharma PLC American Depositary Share$0.17N/AN/AN/A$86.72 millionN/A8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A6.766.76IBRXImmunityBioN/A4.113.98RVMDRevolution Medicines0.1311.7911.79VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIBRXImmunityBio8.58%RVMDRevolution Medicines94.34%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics3.40%IBRXImmunityBio76.79%RVMDRevolution Medicines8.20%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.66 million115.59 millionOptionableIBRXImmunityBio590984.97 million228.61 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableVRNAVerona Pharma PLC American Depositary Share3086.19 million82.06 millionOptionableIBRX, VRNA, RVMD, and CYTK HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Rating of "Hold" by BrokeragesOctober 13 at 2:37 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVerona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to SuspendOctober 8, 2025 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)October 8, 2025 | marketbeat.comMatisse Capital Cuts Holdings in Verona Pharma PLC American Depositary Share $VRNAOctober 8, 2025 | marketbeat.com4,249 Shares in Verona Pharma PLC American Depositary Share $VRNA Acquired by Wealth Enhancement Advisory Services LLCOctober 8, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?October 7, 2025 | marketbeat.comBingham Private Wealth LLC Takes $240,000 Position in Verona Pharma PLC American Depositary Share $VRNAOctober 7, 2025 | marketbeat.comPlatinum Investment Management Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comAMI Asset Management Corp Sells 19,561 Shares of Verona Pharma PLC American Depositary Share $VRNAOctober 2, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Here's WhyOctober 1, 2025 | marketbeat.comVerona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD PortfolioSeptember 30, 2025 | insidermonkey.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Should You Buy?September 25, 2025 | marketbeat.comHere’s What Lifted Verona Pharma (VRNA) in Q2September 25, 2025 | insidermonkey.comShareholders of Verona Pharma Approve Proposed Acquisition by MerckSeptember 24, 2025 | globenewswire.comAtle Fund Management AB Raises Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 21, 2025 | marketbeat.comNorthCrest Asset Manangement LLC Decreases Stock Position in Verona Pharma PLC American Depositary Share $VRNASeptember 21, 2025 | marketbeat.comHarbor Capital Advisors Inc. Invests $1.49 Million in Verona Pharma PLC American Depositary Share $VRNASeptember 19, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Rating of "Hold" by AnalystsSeptember 18, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Here's What HappenedSeptember 17, 2025 | marketbeat.comVerona Pharma (VRNA) Rebounded from Challenging Q1September 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025IBRX, VRNA, RVMD, and CYTK Company DescriptionsCytokinetics NASDAQ:CYTK$59.71 +0.12 (+0.20%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$2.42 -0.07 (-2.62%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Revolution Medicines NASDAQ:RVMD$48.18 -0.57 (-1.16%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.91 0.00 (0.00%) As of 10/7/2025Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
